|
**Overview**: ToRCH Panel IgG Extended**Introduction**: The ToRCH Panel IgG Extended is a diagnostic tool designed for extended congenital infection screening using serum samples. In India, extended IgG testing (Toxoplasma, Rubella, CMV, HSV-1/HSV-2) assesses past exposure/immunity in pregnancy, crucial for risk stratification in high-prevalence settings. High morbidity from under-testing in rural/low-SES pregnant women, limited serology labs, delayed immunity confirmation leading to unnecessary anxiety or missed high-risk cases. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma IgG, Rubella IgG, CMV IgG, HSV-1 IgG, and HSV-2 IgG over 1â€"2 days with high accuracy, valuable for baseline immunity profiling in early pregnancy. This diagnostic falls under infectious disease screening and targets pregnant women in first trimester or high-risk, addressing accurate detection to guide further IgM/avidity or reassurance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling detailed ToRCH immunity assessment and reducing congenital infection burden. Its serum-based approach ensures reliable IgG detection.**Other Names**: TORCH IgG Ext Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Extended ToRCH IgG standard in antenatal care; in India, routine in high-risk pregnancies.**Purpose**: The test assesses 5 parameters including Toxoplasma IgG to guide congenital infection screening, assess past exposure/immunity, inform further testing.**Test Parameters**: 1. Toxoplasma IgG, 2. Rubella IgG, 3. CMV IgG, 4. HSV-1 IgG, 5. HSV-2 IgG.**Pretest Condition**: No fasting required; patients should be pregnant.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, prior infections.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including fetal defects, benefits of extended screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgG indicates past exposure/immunity; HSV-2 positivity flags higher neonatal risk, necessitating specialist input.**Specialist Consultation**: Obstetricians or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: IgM, avidity for recent infection confirmation.**Test Limitations**: IgG only (no acute status); comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023. |
